AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

PrEP

CDC Recommends PrEP for Injection Drug Users

Jonathan Mermin

The Center for Disease Control and Prevention (CDC) today published in the weekly Morbidity and Mortality Weekly Report interim guidance for the use of Preexposure Prophylaxis (PrEP) for the prevention of HIV infection among Injecting Drug Users (IDUs). Results from a randomized controlled trial in Bangkok, Thailand, of a daily oral dose of 300 mg…

Study finds first evidence that PrEP can reduce HIV risk among people who inject drugs

CDC Logo

Daily HIV medications now proven to prevent HIV among all groups at high risk A daily dose of a medication used to treat HIV infection reduced the risk of HIV acquisition among people who inject drugs by 49 percent. Those who took the medication most consistently had even higher levels of protection, according to a…

Conversations from CROI 2013: CDC’s Dr. Jonathan Mermin

Mermin Croi 2013

During the 2013 Conference on Retroviruses and Opportunistic Infections  (CROI) in Atlanta earlier this month, I had the opportunity to sit down with Dr. Jonathan Mermin, Director of CDC’s Division of HIV/AIDS Prevention. We discussed some of the important research findings being shared at the conference and their implications for our efforts to respond effectively…

Daily-use HIV Prevention Approaches Didn’t Work for African Women in the VOICE Study

blog.aids.gov

According to findings of a major HIV prevention trial presented Monday, March 4, 2013 at the 20th Conference on Retroviruses and Opportunistic Infections (CROI), study participants who received daily oral pre-exposure prophylaxis (PrEP) did not experience any protection against HIV compared to those in the placebo arm, likely because very few were taking the study…

FDA approves first drug for reducing the risk of sexually acquired HIV infection

blog.aids.gov

Today (July 16, 2012), the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truvada, taken daily, is to be used for…

FDA Advisory Committees to Examine a Number of HIV Issues in May

FDA

The U.S. Food and Drug Administration (FDA) has three important advisory committee meetings scheduled in May that may impact HIV prevention, detection, and treatment. On May 10, 2012, FDA’s Antiviral Advisory Committee will discuss expanding the indication of Truvada (emtricitabine/tenofovir disoproxil fumarate) tablet, made by Gilead Sciences, Inc., to include use for Pre-Exposure Prophylaxis (PrEP),…

Conversation from CROI: Dr. Jonathan Mermin on PrEP and an AIDS-free Generation

Mermin YouTube still

At the recent 19th Conference on Retroviruses and Opportunistic Infections (CROI), Dr. Ron Valdiserri, Deputy Assistant Secretary of Health for Infectious Diseases, spoke with Dr. Jonathan Mermin, Director of CDC’s Division of HIV/AIDS Prevention. They discussed some of the significant findings from the conference including advances related to pre-exposure prophylaxis (PrEP) and the growing discussions…

Using Pre-Exposure Prophylaxis (PrEP) as a Prevention Tool for MSM: The Promise Comes with Challenges

Ronald Valdiserri

On Saturday, February 26th, I attended a day-long meeting organized by the Centers for Disease Control and Prevention (CDC) and hosted by the Fenway Community Health Center in Boston. The theme of the meeting was “Moving forward with PrEP Implementation.” Meeting participants included researchers involved in the original iPrEX study and other ongoing HIV prevention…

Page 2 of 3123